Cancer News: Leukemia and lymphoma
First gene therapy approved, for acute lymphoblastic leukemia
The US FDA has approved the first gene therapy for use against a type of blood cancer in the United States.
Some leukemia patients may be able to safely stop their treatment
According to new research, some chronic myeloid leukemia (CML) patients may benefit from stopping their Tyrosine Kinase Inhibitor (TKI) treatments.
Chemotherapy seems helpful in patients with follicular lymphoma
Chemotherapy following radiotherapy can improve progression-free survival (PFS) in patients with follicular lymphoma.
Complete response for lymphoma patients with T-cell therapy
Advanced non-Hodgkin lymphoma ((NHL) patients receiving T-cell treatment, JCAR014 and chemotherapy had a complete response, new data show.
Novel drugs expand treatment options for ALL patients
Key findings of the studies including ofatumumab, ponatinib, liposomal vincristine and reduced-intensity therapy for the treatment of ALL patients.
Updates on therapy options for older AML & CLL patients
Promising results from treatment options for older patients with acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL).
Venetoclax promising for acute myelogenous leukemia
Venetoclax induced promising outcomes to acute myelogenous leukemia patients whose disease had relapsed or was resistant to chemotherapy, a trial shows.
Mantle cell lymphoma: lenalidomide gets EU approval
REVLIMID® (lenalidomide) received approval by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Hodgkin lymphoma: closer to cure with immunotherapy
Hodgkin lymphoma patients remained disease-free for over five years after being treated with the immunotherapy brentuximab vedotin, new data shows.
FDA approves molecular diagnostic for chronic myeloid leukemia
US regulator approved the marketing of a molecular diagnostic test measuring BCR-ABL levels in patients with chronic myeloid leukemia (CML).
Immunotherapy blinatumomab brings hope to ALL patients
Immunotherapy drug blinatumomab extended patients life with relapsed acute lymphoblastic leukemia when compared to chemotherapy.
Ibrutinib gets EU approval for newly diagnosed CLL
EU regulators approved ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).
Nivolumab gets US accelerated approval for Hodgkins lymphoma
US regulators granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma.
FDA approves new targeted therapy for CLL
US regulators approved AbbVie’s drug venetoclax to treat patients with previously treated chronic lymphocytic leukemia.
Assessing treatment in Hodgkin Lymphoma with PET-CT
Positron emission tomography-computed found to be a new standard for staging patients with Hodgkin lymphoma as well as for assessment of treatment response.
Obinutuzumab gets FDA’s green light for follicular lymphoma
US regulators have approved obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma.
Childhood Hodgkin's lymphoma survivors are at risk of breast cancer
Childhood Hodgkin's lymphoma survivors are at risk of breast cancer say researchers, adding that early screening reduces risk of breast cancer death.
US regulators grant breakthrough therapy for AML treatment
Novartis’ investigational drug, midostaurin, received breakthrough therapy designation for US regulators for acute myeloid leukemia.
Childhood leukemia survivors at risk for learning problems
Pediatric acute lymphoblastic leukemia patients treated with chemotherapy alone remain at risk for attention and learning problems later, researchers report.
Arzerra gets US approval against chronic lymphocytic leukemia
US regulators approved Arzerra, to be used as an extended treatment against recurrent or progressive chronic lymphocytic leukemia.
Post-treatment care for young Hodgkin lymphoma survivors
A new study identifies the gaps in post-treatment care for adolescent and young-adult Hodgkin lymphoma survivors.
Linking breast cancer treatment and leukemia
Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.
Experimental drug improves survival in high-risk AML patients
The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.
Blinatumomab brings hope to acute lymphoblastic leukemia patients
Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.
Imbruvica shows better results than chemo in leukemia patients
Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.
Best treatment option for breast implant-associated cancer
Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.
New treatment for acute lymphoblastic leukemia approved in EU
EU regulators approved blinatumomab for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia.
Combination therapy gives hope to mantle cell lymphoma patients
Patients with mantle cell lymphoma benefited from the drug combination of rituximab plus lenalidomide, a new study shows.
Vemurafenib appears effective in hairy cell leukemia
A short course of oral vemurafenib was found to be highly effective in patients with relapsed/refractory hairy cell leukemia, two separate, phase 2 studies reveal.
Conditional European approval for a rare blood cancer drug
The European health regulators conditionally approved Blincyto, a treatment for acute lymphoblastic leukemia (ALL), a rare blood cancer.